Skip to main content
US EQUITIES AFTER-HOURS CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
ZB

ZBIOStockZenas BioPharma, Inc.

Nasdaq Global Select Market · Healthcare · US

$23.85 last close 2026-11-20
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment ZBIO's does — no target price to set, unlike a price alert.

Stable Ratio screen, 0 of 5 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
NOT COMPLIANT
Per our in-house ratio engine · assessed 2026-08-28
Assessed 2026-08-28
0 of 5 pass our own screen — 2 of 7 could not be computed
Purification 100.00% *
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 5 timeframes bullish · 100.0% aligned
VWAPPrice below VWAP ($26.66)
VolumeRelative volume 3.8× the 20-day average
Momentum10-day rate of change -15.6%

Zenas BioPharma, Inc. (ZBIO) is currently considered not halal (non-compliant), per our in-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

434 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts
Price target
$47.88
+100.7% · 8 analysts
Institutional own.
102.3% *
of shares
Momentum (10d)
-15.6%
rate of change
SMC grade
F · 33
100.0% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
F · 33
SMC grade — 100.0% timeframe alignment
-15.6%
Rate of change (10d)
$47.88
Price target (+100.7%) · 8 analysts
102.3%
Institutional ownership *

How the status reached this point

Non-compliant · status tracked since Nov 17, 2026

No change to ZBIO’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 19, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $1.9B as of 2026-11-20.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail 2 of 3 computed, 1 passes, 1 fails
RatioValueThresholdResult
Interest-bearing debt (bound) at most 25.02% 30.00% Pass
Interest-bearing investments 31.63% 30.00% Fail(1.6pp over)
Non-permissible income
non-permissible income $12,151,000 exceeds reported revenue $10,000,000 — the revenue tag is not total income for this filer
not available 5.00% Unverified
Usmani Fail 3 of 5 computed, 1 passes, 2 fail
RatioValueThresholdResult
Interest-bearing debt
debt not reported
not available 33.00% Unverified
Interest-bearing investments 86.69% 33.00% Fail(53.7pp over)
Non-liquid assets 13.31% at least 20.00% Fail(6.7pp below the floor)
Non-permissible income
non-permissible income $12,151,000 exceeds reported revenue $10,000,000 — the revenue tag is not total income for this filer
not available 5.00% Unverified
Net liquid assets per share $521.3M under mkt cap $1.9B Pass
MSCI Fail 2 of 4 computed, both fail
RatioValueThresholdResult
Interest-bearing debt
debt not reported
not available 33.33% Unverified
Cash + interest-bearing securities 86.69% 33.33% Fail(53.4pp over)
Accounts receivable 86.69% 33.33% Fail(53.4pp over)
Non-permissible income
non-permissible income $12,151,000 exceeds reported revenue $10,000,000 — the revenue tag is not total income for this filer
not available 5.00% Unverified
FTSE Fail 2 of 4 computed, both fail
RatioValueThresholdResult
Interest-bearing debt
debt not reported
not available 33.33% Unverified
Cash + interest-bearing securities 86.69% 33.33% Fail(53.4pp over)
Accounts receivable 86.69% 50.00% Fail(36.7pp over)
Non-permissible income
non-permissible income $12,151,000 exceeds reported revenue $10,000,000 — the revenue tag is not total income for this filer
not available 5.00% Unverified
Dow Jones Islamic Market Fail 2 of 4 computed, 1 passes, 1 fails

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt
debt not reported
not available 33.00% Unverified
Cash + interest-bearing securities 41.99% 33.00% Fail(9.0pp over)
Accounts receivable 0.00% 33.00% Pass(33.0pp buffer)
Non-permissible income
non-permissible income $12,151,000 exceeds reported revenue $10,000,000 — the revenue tag is not total income for this filer
not available 5.00% Unverified

ℹ️ MSCI M-Series, S&P Shariah divide by a trailing-average market cap (24- or 36-month) rather than today's. That price history is not collected for non-US listings, so these are reported as unverified — it reflects a missing input on our side, not anything about the company.

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Dow Jones Islamic Market (% of 24-mo avg market cap)receivables ratio 33.0pts
Usmani (% of total assets)investments ratio 53.7pts
MSCI Islamic Index (% of total assets)cash and interest ratio 53.4pts
MSCI Islamic Index (% of total assets)receivables ratio 53.4pts

The numbers the ratios are built from

Read from ZBIO's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $10.0M 2025-12-31 Revenues
Interest-bearing debtBorrowings — which definition was stored is not recorded not measured — —
Cash and interest-bearing securitiesCash, equivalents and marketable securities $585.3M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, ShortTermInvestments
Total assetsBalance sheet total $675.2M 2026-09-30 Assets
Market capDenominator for AAOIFI $1.9B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series not measured — —
24-month average market capDenominator for Dow Jones Islamic Market $1.3B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $12.2M 2025-12-31 InvestmentIncomeInterest

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-05, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-03-16, period ended 2025-12-31. Screened 2026-11-20.

  • Total assets$675.2M
    Assets · period ended 2026-09-30 · 10-Q filed 2026-11-05
  • Cash and interest-bearing securities$585.3M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents $177.8M · period ended 2026-09-30 · 10-Q filed 2026-11-05
    ShortTermInvestments $407.5M · period ended 2026-09-30 · 10-Q filed 2026-11-05
  • Receivables$0
    no receivables tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30 · no filing link for this figure
  • Revenue$10.0M
    Revenues · period ended 2025-12-31 · 10-K filed 2026-03-16
  • Interest income (non-permissible)$12.2M
    InvestmentIncomeInterest · period ended 2025-12-31 · 10-K filed 2026-03-16
  • Market cap$1.9B
    Market quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-19 · not a filing figure, so no link

5 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.

What changed, and when

Verdict history for ZBIO. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for ZBIO has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 0 pass and 5 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-20.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's investments ratio is $585.3M cash and interest-bearing investments over a market cap of $1.9B (as of 2026-11-20), 31.6% against a 30% line.

It would pass if the market cap rose above $2.0B (+5%), about $28.77 a share against $27.28 implied by the screen's own figures.

AAOIFI would then be unverified; the majority verdict would stay Not compliant (0 of 4 decided standards passing).

At the screen's market cap, it would take $30.2M less cash and interest-bearing investments to clear the line.

AAOIFI would then be unverified; the majority verdict would stay Not compliant (0 of 4 decided standards passing, counting every standard that divides the same figure).

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold ZBIO

6 of the 260 funds whose filed holdings we currently hold own ZBIO shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns ZBIO.

You may already own it

Widely held U.S. index funds. If you own one, you own ZBIO through it. None of them is a Shariah fund; the last column is our look-through of each.

FundZBIO in fundFund compliant by weight
SCHB Schwab U.S. Broad Market ETF 0.00% 53%
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00% 54%
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.00% 54%
Other funds
FundZBIO in fundFund compliant by weight
PRNHX T. Rowe Price New Horizons Fund, Inc. 0.08% 51%
VTHR VANGUARD RUSSELL 3000 INDEX FUND 0.00% 52%
DFAS Dimensional U.S. Small Cap ETF 0.00% 37%

Sorted by ZBIO’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names ZBIO once, so a bond is not counted as the shares; 1 more fund name ZBIO in a way we cannot separate from its bonds, and is not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding ZBIO
InvestorFirmPositionWeightAs of
Ken Griffin Citadel Advisors $8M 0.0% 2026-09-30
Israel Englander Millennium Management $5M 0.0% 2026-09-30
Steven Cohen Point72 Asset Management $3M 0.0% 2026-09-30
Paul Tudor Jones Tudor Investment Corp $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

43.1736.1829.1822.1915.202025-11-212026-05-262026-11-20

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
22.10
S2
23.52
S1
24.28
PIVOT
25.70
R1
26.46
R2
27.88
R3
28.64

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
21.71 – 32.19
±19.43% from 26.95, made 2026-09-25 · resolves 2026-10-02
STRONG SELL
from 19 indicators
78.6% of our last 30385 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)33.10NEUTRAL
Stochastic %K (14)1.12BUY
CCI (20)-274.64BUY
Williams %R (14)-98.88BUY
MACD (12,26,9)-0.37SELL
ROC (10)-15.61SELL
Momentum (10)-4.41SELL
EMA (10)26.60SELL
SMA (10)27.25SELL
EMA (20)27.17SELL
SMA (20)27.58SELL
EMA (30)27.47SELL
SMA (30)27.21SELL
EMA (50)27.88SELL
SMA (50)27.99SELL
EMA (100)27.85SELL
SMA (100)29.52SELL
EMA (200)26.72SELL
SMA (200)25.51SELL

About Zenas BioPharma, Inc.

Healthcare · Biotechnology

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

zenasbio.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

No real edge — avoid

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 44
⏰ 4H BEARISH 36
🕐 1H BEARISH 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-15.6%
Rate of change (10d)
3.8×
Volume vs its 20-day average
-0.48
MACD (no fresh cross)
$23.94
Volume POC (today)
$23.79 – $24.78
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-17 · Asset managers net 895049 (-19081)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.